Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M123,936Revenue $M18,676Net Margin (%)24.7Z-Score2.6
Enterprise Value $M128,841EPS $6.6Operating Margin %30.0F-Score5
P/E(ttm))25.7Cash Flow Per Share $6.7Pre-tax Margin (%)26.9Higher ROA y-yN
Price/Book4.910-y EBITDA Growth Rate %11.0Quick Ratio3.9Cash flow > EarningsY
Price/Sales6.45-y EBITDA Growth Rate %8.7Current Ratio4.2Lower Leverage y-yY
Price/Cash Flow13.3y-y EBITDA Growth Rate %15.5ROA % (ttm)7.4Higher Current Ratio y-yN
Dividend Yield %1.5Insider Buy (3m)0ROE % (ttm)21.0Less Shares Outstanding y-yN
Payout Ratio %36.0Shares Outstanding M761ROI % (ttm)8.2Gross Margin Increase y-yN

Gurus Latest Trades with AMGN

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

AMGN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
AMGN Jean-Marie Eveillard 2014-09-30714,1780.090.25New Buy
AMGN Ruane Cunniff 2014-09-301,61700New Buy
AMGN Daniel Loeb 2014-09-301,325,0000.172.1+194.44%
AMGN Ken Fisher 2014-09-30156,6290.020.05+83.59%
AMGN PRIMECAP Management 2014-09-3031,793,8734.184.8-0.19%
AMGN Mario Gabelli 2014-09-3059,9500.010.05-0.64%
AMGN Vanguard Health Care Fund 2014-09-307,022,7550.922.5-12.75%
AMGN Dodge & Cox 2014-09-3072,9070.010.01-15.08%
AMGN John Hussman 2014-09-3025,00000.3-50%
AMGN Joel Greenblatt 2014-09-302,69300-72.9%
AMGN Mark Hillman 2013-12-317,91201.4-1.95%
Premium Most recent portfolio changes are included for Premium Members only!

AMGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Harper Sean EEVP, Research & Development 2014-08-05Sell14,000$127.2929.54view
Patton Cynthia MSVP & CCO 2014-08-05Sell2,644$127.9728.85view
Dittrich Thomas J.W.VP, Finance & CAO 2014-05-21Sell4,130$112.8346.14view
Bradway Robert AChairman, CEO and President 2014-05-12Buy894$111.7747.53view
Michael A KellyActing CFO 2014-04-28Sell2,065$110.4549.29view
Piacquad DavidSVP, Business Development 2014-03-10Sell0$049.29view
de Carbonnel FrancoisDirector 2014-03-06Sell1,000$126.6930.15view
HENDERSON REBECCA MDirector 2014-02-13Sell20,000$123.5333.48view
Michael A KellyActing CFO 2014-01-10Sell0$033.48view
AMGEN INC10% Owner 2013-12-17Buy272,142$72255.57view

Press Releases about AMGN :

    Quarterly/Annual Reports about AMGN:

    News about AMGN:

    Articles On GuruFocus.com
    Amgen: Stronger Drug Portfolio with Acquisition Oct 28 2014 
    Daniel Loeb Comments on Amgen Inc Oct 22 2014 
    Third Point Q3 2014 Investor Letter Oct 22 2014 
    Amgen: Stronger Drug Portfolio with Acquisition Sep 22 2014 
    Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014 
    Weekly 52-Week Highs Highlight: ABT, SWK, LMT, AMGN Sep 13 2014 
    After Reaching All-Time Highs, How Can Gilead Sciences Continue growing? Aug 27 2014 
    Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and AstraZeneca (AZN) Positive Data From May 11 2014 
    Amgen Inc: As Good as It Gets? Feb 20 2014 
    You Can No Longer Ignore Biotech Feb 07 2014 

    More From Other Websites
    Amgen ends studies of gastric cancer drug Nov 24 2014
    Amgen ends studies of gastric cancer drug Nov 24 2014
    JANA Partners opens a stake in Amgen Nov 24 2014
    Amgen Ends Trials of Stomach-Cancer Therapy Nov 24 2014
    Amgen Surprise, Discontinues Stomach Cancer Drug Study Nov 24 2014
    Amgen ends trials of stomach-cancer therapy Nov 24 2014
    Amgen Stops Gastric-Cancer Drug Trials on Increase in Deaths Nov 24 2014
    Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced... Nov 24 2014
    Amgen scraps trials of drug for advanced stomach cancer Nov 24 2014
    9:17 am Amgen announced the termination of all AMGN sponsored clinical studies of rilotumumab in... Nov 24 2014
    Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced... Nov 24 2014
    Motley Fool: Pundits pandering your wealth away Nov 22 2014
    Amgen and AbbVie Strengthen Manufacturing Facilities in Asia Nov 21 2014
    Fighting kids' cancer... fixing a broken system Nov 21 2014
    New data fuels doctors' demands to rewrite U.S. heart guidelines Nov 21 2014
    SINGAPORE PRESS-Amgen opens S$200 mln plant in Singapore-Straits Times Nov 20 2014
    Amgen Opens Next-generation Biomanufacturing Facility in Singapore Nov 19 2014
    Amgen Inc Conference Call to Discuss Evolocumab Development Program at AHA scheduled for 7:00 pm ET... Nov 18 2014
    Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering... Nov 18 2014
    Amarantus unterzeichnet exklusive Optionsvereinbarung zum Erwerb eines gezüchteten Hautersatzes... Nov 17 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial